Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + ganitumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Everolimus (RAD001) is an orally administered small molecule inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth, proliferation, and survival. Ganitumab (AMG 479) is a fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), inhibiting its activation by IGF ligands and thereby blocking downstream signaling involved in tumor cell proliferation and survival. The combination has been investigated in phase I clinical trials for advanced solid tumors, including colorectal cancer and non-small cell lung cancer, to assess safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy. Everolimus is approved for several cancers under the brand name Afinitor; ganitumab remains investigational[1][2][3][4][5].
- Brand names
- Afinitor
- Other names
- RAD001 + AMG479everolimus + ganitumabganitumab + everolimus
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on everolimus + ganitumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + ganitumab.